Designing a Topical Nanoliposomal Formulation of Ruxolitinib Phosphate

Designing a Topical Nanoliposomal Formulation of Ruxolitinib Phosphate

Background: The JAK-STAT pathway has been revealed to play a crucial role in the dysregulation of immune responses in autoimmune skin disorders. Ruxolitinib, a selective inhibitor of JAK1 and JAK2, potently suppresses cytokine signaling. Methods: A topical emulgel containing ruxolitinib nanoliposom...

Full description

Bibliographic Details
Main Authors:	Atefeh Naeimifar, Saman Ahmad Nasrollahi, Hamid Akbari Javar, Mansoor Nassiri Kashani, Alireza Firooz, Mohamadreza Rouini
Format:	Article
Language:	English
Published:	Tabriz University of Medical Sciences 2023-01-01
Series:	Pharmaceutical Sciences
Subjects:	autoimmune dermatological disorders cytokine signaling dsc nanoliposomes ruxolitinib sem
Online Access:	https://ps.tbzmed.ac.ir/PDF/ps-29-75.pdf

Similar Items

Evaluation of tolerability and efficacy of a topical emulgel containing nanoliposomal ruxolitinib phosphate in the treatment of mild atopic dermatitis: a before-after single group pilot study
by: Atefeh Naeimifar, et al.
Published: (2022-11-01)

Gamma Oryzanol Bearing Nanoliposome Produced by Modified Thermal Method: Thermal Property, Encapsulation Efficiency, Oscillatory Rheometry
by: Z. Mohammad Hassani, et al.
Published: (2014-01-01)

Efficacy of topical ruxolitinib for cutaneous dermatomyositis
by: Aviya Lanis, MD, et al.
Published: (2024-03-01)

Encapsulation of Vitamins Using Nanoliposome: Recent Advances and Perspectives
by: Masoud Aman Mohammadi, et al.
Published: (2023-01-01)

Letter in response to the case report “Topical ruxolitinib in the treatment of refractory facial seborrheic dermatitis”
by: Meron Teklu, MD, et al.
Published: (2023-12-01)

Successful treatment of alopecia totalis with ruxolitinib in a preadolescent patient
by: Danielle M. Peterson, MD, et al.
Published: (2020-04-01)

Topical ruxolitinib in the treatment of refractory facial seborrheic dermatitis
by: Eleanor Pope, BA, et al.
Published: (2022-06-01)

Severe ARDS due to Ruxolitinib discontinuation syndrome: case presentation and literature review
by: Jona F. Houthuys, et al.
Published: (2022-12-01)

Preclinical toxicity assessment of anionic nanoliposomes
by: Amir Abbas Momtazi-Borojeni, et al.
Published: (2024-01-01)

Production and Evaluation of Nanoliposomes Loaded with Capparis spinosa Extract
by: Masoumeh Salamatian, et al.
Published: (2023-03-01)

Transnasal nimodipine-loaded mucoadhesive nanoliposomes: Preparation and in-vitro evaluation
by: Nozad Rashid Hussein, et al.
Published: (2019-08-01)

Preparation of Benzothiazolyl-Decorated Nanoliposomes
by: Spyridon Mourtas, et al.
Published: (2019-04-01)

Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms
by: Eylem Eliaçık, et al.
Published: (2015-05-01)

Application of Nanoliposomes Containing Nisin and Crocin in Milk
by: Mohammad Yousefi, et al.
Published: (2023-01-01)

Ruxolitinib cream for the treatment of cutaneous sarcoidosis
by: Jeffrey S. Smith, MD, PhD, et al.
Published: (2023-08-01)

Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan
by: Ko AH
Published: (2016-03-01)

Physicochemical Properties of Nanoliposomes Encapsulating Grape Seed Tannins Formed with Ultrasound Cycles
by: Angela Monasterio, et al.
Published: (2024-01-01)

A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis
by: Francesca Palandri, et al.
Published: (2023-10-01)

Preparation, Characterization and Cytotoxic Studies of Cisplatin-containing Nanoliposomes on Breast Cancer Cell Lines
by: Fateme Mohammadinezhad, et al.
Published: (2023-07-01)

Nanoliposomes and Nanoemulsions Based on Chia Seed Lipids: Preparation and Characterization
by: Daria V. Kuznetcova, et al.
Published: (2020-11-01)

Off-label studies on ruxolitinib in dermatology: a review
by: Jessica Wu, et al.
Published: (2022-02-01)

Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib
by: Sakiyama E, et al.
Published: (2020-04-01)

Treatment of granulomatous perioral dermatitis with 1.5% topical ruxolitinib cream
by: Sophia S. Tran, BS, et al.
Published: (2024-05-01)

Features of lyophilization of a nanoliposomal drug
by: V. G. Pushkar, et al.
Published: (2016-10-01)

Ruxolitinib: a targeted treatment option for patients with polycythemia vera
by: Vaddi K, et al.
Published: (2016-05-01)

Tuberculosis in Patients with Primary Myelofibrosis During Ruxolitinib Therapy: Case Series and Literature Review
by: Peng Y, et al.
Published: (2020-09-01)

Improvement of necrobiosis lipoidica with topical ruxolitinib cream after prior nonresponse to compounded topical tofacitinib cream
by: Shannon Nugent, BS, et al.
Published: (2022-11-01)

Controlled Assembly of Fluorophores inside a Nanoliposome
by: Hiroaki Konishi, et al.
Published: (2023-01-01)

Nanoliposomes in Cancer Therapy: Marketed Products and Current Clinical Trials
by: Raquel Taléns-Visconti, et al.
Published: (2022-04-01)

Nanoliposomes as Vehicles for Astaxanthin: Characterization, In Vitro Release Evaluation and Structure
by: Li Pan, et al.
Published: (2018-10-01)

Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report
by: Meltem Aylı, et al.
Published: (2015-05-01)

Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system
by: Vincenzo Accurso, et al.
Published: (2019-03-01)

Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib
by: Arthur E. Frankel, et al.
Published: (2021-04-01)

Ruxolitinib-Associated Infections in Polycythemia Vera: Review of the Literature, Clinical Significance, and Recommendations
by: Parvis Sadjadian, et al.
Published: (2020-10-01)

Ruxolitinib as a Novel Therapeutic Option for Poor Prognosis T-LBL Pediatric Patients
by: Giulia Veltri, et al.
Published: (2021-07-01)

In vitro evaluation of antileishmanial activity of Boswellia serrata essential oil nanoliposome
by: Mohaddeseh Babaei, et al.
Published: (2024-03-01)

Preparation and Optimization of Ibrutinib-Loaded Nanoliposomes Using Response Surface Methodology
by: Fareeaa Ashar, et al.
Published: (2022-09-01)

Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real‐life setting: An Italian MYNERVA Project
by: Giacomo Coltro, et al.
Published: (2023-04-01)

Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis
by: Simone Claudiani, et al.
Published: (2021-09-01)

Case of Pulmonary Extramedullary Hematopoiesis Responding to Ruxolitinib
by: Ayumi Fujimoto, et al.
Published: (2022-01-01)